Polyclonal allergen-specific immunoglobulin E (IgE)

Polyclonal allergen-specific immunoglobulin E (IgE) is a specialized class of antibody that plays a central role in type I hypersensitivity reactions (StatPearls, 2023). Produced by plasma cells in response to environmental allergens, these antibodies circulate in the blood and bind with high affinity to FcεRI receptors on the surface of mast cells and basophils (Nature Reviews Immunology, 2008). When a sensitized individual is re-exposed to the specific allergen, the allergen cross-links the surface-bound IgE, triggering the immediate release of inflammatory mediators such as histamine, leukotrienes, and cytokines (Journal of Allergy and Clinical Immunology, 2016). This process is responsible for the clinical manifestations of allergic diseases, including allergic asthma, hay fever, and systemic anaphylaxis (World Allergy Organization, 2021). Therapeutic targeting of IgE, primarily through monoclonal antibodies like omalizumab, aims to sequester free circulating IgE, thereby preventing effector cell activation and reducing the chronic inflammatory response (DrugBank, 2024). This approach has become a cornerstone in managing severe persistent allergic asthma and chronic spontaneous urticaria.

Other names

Allergen-specific IgEsIgEReaginic antibodyImmunoglobulin EIgE antibody

Therapeutic monoclonal antibodies bind to the Cε3 domain of free circulating IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils, which subsequently leads to the downregulation of these receptors and the inhibition of the allergic inflammatory cascade.